Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says


Every human life is precious and sacred and saving one is like saving the whole of humanity. (Al Quran 5:32/33)

(CNN) Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% efficacy against severe disease, the company announced Friday.

The vaccine was 72% effective against moderate and severe disease in the US, the company said.
It’s a striking difference from vaccines from Pfizer/BioNTech and Moderna, and it may give pause to people uncertain about which vaccine to get or when they can get one. The vaccines already on the market in the US are about 95% effective overall against symptomatic Covid-19, with perhaps even higher efficacy against severe cases.

But experts say the Johnson & Johnson vaccine will still be useful against the pandemic in the United States and around the world.

Read further

Categories: Vaccine

3 replies

  1. Johnson & Johnson board member Dr. Mark McClellan told CNBC Friday that there could be enough vaccinations for the entire U.S. adult population by the summer.

    “Assuming all of the close review of the J&J data all pans out, we’re going to have the capacity between Moderna, Pfizer, J&J, to have enough vaccines available by June for the entire U.S. adult population,” McClellan, a former FDA commissioner, said on “The News with Shepard Smith.”

    The U.S. plans to buy 200 million Covid vaccine doses from Moderna and Pfizer. The Department of Health and Human Services will boost its vaccine supply to states from 8.6 million to a minimum of 10 million doses per week. So far, states have received more than 49 million doses, but only about half of those have actually ended up in people’s arms, according to the Centers for Disease Control and Prevention. The agency reports that the U.S. is administering a little more than a million shots every day.

  2. (CNN)Johnson & Johnson officially asked the US Food and Drug Administration for an emergency use authorization of its Covid-19 vaccine Thursday.

    Covid-19 vaccine rollout puts a spotlight on unequal internet access
    Covid-19 vaccine rollout puts a spotlight on unequal internet access
    “Today’s submission for Emergency Use Authorization of our investigational single-shot COVID-19 vaccine is a pivotal step toward reducing the burden of disease for people globally and putting an end to the pandemic,” Dr. Paul Stoffels, Chief Scientific Officer at Johnson & Johnson, said in a statement.
    As the FDA looks at the results, it will schedule a public meeting of its Vaccines and Related Biological Products Advisory Committee, an independent group of experts who will also look at the data and make a recommendation that the agency takes into consideration when it makes a decision.
    Content by Rosetta Stone
    M&M’S that really say “I Love You”
    From heart-shaped candy boxes to romantic gift jars, M&M’S makes it easy to send that special someone something, well, special (and sweet!).
    If the FDA decides to authorize the vaccine, next the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices meets to discuss whether the vaccine should be given to Americans and if so, who should get it first.
    Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says
    Johnson & Johnson Covid-19 vaccine is 66% effective in global trial, but 85% effective against severe disease, company says
    This same regulatory process for Pfizer took a little over three weeks. For Moderna it was a little more than two.
    The Johnson & Johnson vaccine is a little different than the other Covid-19 vaccines. The vaccine, made through a collaboration of J&J’s vaccine division, Janssen Pharmaceutical, and Beth Israel Deaconess Medical Center in Boston, is delivered in a single shot. Pfizer and Moderna’s require two. It’s considered versatile since it is considered stable for up to three months kept in regular refrigerated temperatures and doesn’t need the deep freeze like Pfizer’s.

  3. Johnson & Johnson asked U.S. drug regulators to clear its experimental Covid-19 vaccine for emergency use, setting off a review process that could lead to millions more doses becoming available to step up a stumbling immunization drive.

    The drugmaker said in a statement Thursday that it had filed an application for an emergency-use authorization with the U.S. Food and Drug Administration. If cleared, the shot would give the U.S. a third vaccine to try to halt a pandemic that has killed more than 450,000 Americans.

    In the coming weeks FDA officials will examine J&J’s trial data, and the agency scheduled a Feb. 26 meeting at which a panel of outside advisers will consider the request for clearance and make a recommendation about whether to grant it. While its decision isn’t binding, it is unusual for the FDA to reject the experts’ advice.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.